{"id":70483,"date":"2026-07-23T21:09:45","date_gmt":"2026-07-23T13:09:45","guid":{"rendered":"https:\/\/flcube.com\/?p=70483"},"modified":"2026-07-23T21:09:47","modified_gmt":"2026-07-23T13:09:47","slug":"takeda-secures-worlds-first-nmpa-approval-for-orexatone-novel-oral-ox2r-agonist-for-type-1-narcolepsy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70483","title":{"rendered":"Takeda Secures World’s First NMPA Approval for Orexatone \u2013 Novel Oral OX2R Agonist for Type 1 Narcolepsy"},"content":{"rendered":"\n

Takeda Pharmaceutical Company Limited<\/strong> (TYO: 4502<\/a>; NYSE: TAK<\/a>) announced that China’s National Medical Products Administration (NMPA)<\/strong> has granted marketing approval<\/strong> for Orexatone<\/strong>, an oral selective orexin 2 receptor (OX2R) agonist<\/strong> indicated for the treatment of patients aged 16 and older with type 1 narcolepsy (NT1)<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Full marketing approval<\/td><\/tr>
Product<\/strong><\/td>Orexatone tablets (oral)<\/td><\/tr>
Indication<\/strong><\/td>Treatment of patients \u226516 years with type 1 narcolepsy (NT1)<\/td><\/tr>
Approval Date<\/strong><\/td>23 Jul 2026<\/td><\/tr>
Significance<\/strong><\/td>World’s first market approval for Orexatone<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n